Phase I Trial Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients
Summary
The purpose of this phase I trial is to study the side effects and best dose of disulfiram when given together with gemcitabine hydrochloride in treating patients with an unresectable solid tumor or metastatic pancreatic cancer, and to compare whether disulfiram and gemcitabine hydrochloride may reduce tumor induced muscle loss.
General Information
NCT#: NCT02671890
Study ID: MC1512
Trial Phase: Phase I
Trial Sponsor: National Cancer Institute (NCI), Mayo Clinic
Therapies Used in This Trial: Gemcitabine, Disulfiram